A. Howe

Preclinical safety and efficacy of an anti–HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

K. Cornetta, I. Chen, J. Bartlett, 2014, Molecular therapy. Methods & clinical development.

Mapping the extent of heterogeneity of human CCR5+ CD4 T-cells in peripheral blood and lymph nodes.

A. Kelleher, J. Zaunders, N. Saksena, 2020, AIDS.

High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells

T. Phan, A. Kelleher, J. Zaunders, 2022, Frontiers in Immunology.

Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies.

S. Ferrone, R. Seeger, A. Howe, 1981, Journal of the National Cancer Institute.

Analysis and dissociation of anti‐HIV effects of shRNA to CCR5 and the fusion inhibitor C46

P. Gorry, S. Turville, J. Murray, 2018, The journal of gene medicine.

Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response

T. Phan, A. Kelleher, J. Zaunders, 2021, iScience.

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

J. Juno, D. Darley, Chansavath Phetsouphanh, 2022, Nature Immunology.